Y Intercept Hong Kong Ltd Takes $1.95 Million Position in Vera Therapeutics, Inc. $VERA

Y Intercept Hong Kong Ltd bought a new position in Vera Therapeutics, Inc. (NASDAQ:VERA) in the third quarter, according to the company in its most recent filing with the SEC. The fund bought 67,193 shares of the company’s stock, valued at approximately $1,953,000.

Several other large investors have also recently modified their holdings of the stock. Quantbot Technologies LP bought a new stake in Vera Therapeutics in the second quarter worth $51,000. Virtus Investment Advisers LLC raised its stake in shares of Vera Therapeutics by 14.8% in the second quarter. Virtus Investment Advisers LLC now owns 4,176 shares of the company’s stock valued at $98,000 after acquiring an additional 539 shares during the period. Tower Research Capital LLC TRC lifted its holdings in shares of Vera Therapeutics by 192.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock worth $99,000 after acquiring an additional 2,757 shares during the last quarter. Fifth Third Bancorp purchased a new position in shares of Vera Therapeutics during the 2nd quarter worth about $102,000. Finally, Ameritas Investment Partners Inc. boosted its stake in shares of Vera Therapeutics by 13.3% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,254 shares of the company’s stock worth $124,000 after purchasing an additional 615 shares during the period. Institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Trading Down 3.5%

VERA opened at $45.11 on Thursday. The company has a quick ratio of 12.21, a current ratio of 12.21 and a debt-to-equity ratio of 0.19. The stock’s fifty day moving average is $45.25 and its two-hundred day moving average is $32.32. The company has a market capitalization of $2.88 billion, a P/E ratio of -11.31 and a beta of 1.16. Vera Therapeutics, Inc. has a 52 week low of $18.53 and a 52 week high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.06). During the same period last year, the company earned ($0.85) earnings per share. Analysts forecast that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on VERA shares. The Goldman Sachs Group raised their price objective on shares of Vera Therapeutics from $55.00 to $95.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. Evercore ISI raised their price target on Vera Therapeutics from $75.00 to $97.00 and gave the stock an “outperform” rating in a research note on Monday, December 8th. Cantor Fitzgerald restated an “overweight” rating on shares of Vera Therapeutics in a report on Wednesday, November 26th. Wedbush increased their target price on Vera Therapeutics from $23.00 to $33.00 and gave the stock a “neutral” rating in a research note on Thursday, December 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vera Therapeutics in a research report on Wednesday, January 21st. Nine investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $74.83.

Insider Activity

In other Vera Therapeutics news, Director Patrick G. Enright bought 5,882 shares of the company’s stock in a transaction on Thursday, December 11th. The shares were bought at an average cost of $42.50 per share, for a total transaction of $249,985.00. Following the acquisition, the director directly owned 5,882 shares in the company, valued at approximately $249,985. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Joseph R. Young sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $29.06, for a total transaction of $435,900.00. Following the transaction, the senior vice president directly owned 47,839 shares in the company, valued at $1,390,201.34. This trade represents a 23.87% decrease in their position. The SEC filing for this sale provides additional information. 16.30% of the stock is owned by corporate insiders.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.